Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome

Boudreaux, Alison A.; Smith, Laura; Cosby, Cecily D.; Bason, Margaret M.; Tappero, Jordan W.; Berger, Timothy G.

doi:10.1016/0190-9622(93)70010-q

Cited by 96 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For cutaneous KS lesions, a total response of 88% was reported. 22 In general, smaller lesions were more likely to respond and repeated injections were often necessary. The most common side effect was inflammatory hyperpigmentation and recurrences within 4-6 months were common.…”

Section: Intralesional and Topical Chemotherapymentioning

confidence: 99%

Therapeutic strategies for epidemic Kaposi's sarcoma

2006

View full text Add to dashboard Cite

Kaposi's sarcoma (KS) remains the most commonly diagnosed malignancy in HIV-infected patients, and is one of the AIDS-defining diagnoses. Several different therapeutic options are available, but the optimal therapy is still unclear. The incidence of KS has sharply declined since highly active antiretroviral therapy (HAART) became widely available, making HAART indispensable in the treatment of epidemic KS. HAART can be given alone or in combination with systemic and local therapy. Systemic therapy can be given in disseminated, progressive or symptomatic disease. Treatment options are interferon-alpha and chemotherapy including pegylated-liposomal anthracyclines and paclitaxel. For local disease, radiotherapy, intralesional chemotherapy or cryotherapy may be used. In resource-limited settings, intravenous vincristine, oral etoposide or intramuscular bleomycin may be feasible options. Other therapies, such as angiogenesis inhibitors, are under investigation in clinical trials.

show abstract

Section: Intralesional and Topical Chemotherapymentioning

confidence: 99%

Therapeutic strategies for epidemic Kaposi's sarcoma

2006

View full text Add to dashboard Cite

show abstract

“…250 Table IV summarizes the various treatment modalities. There are many different options for local treatment of a small number of lesions. 251 These include radiation, 252,253 electron beam, 254 photodynamic therapy, 255,256 liquid nitrogen, 257 intralesional vinca alkaloids, [258][259][260][261][262] intralesional interferon-a, 263,264 intralesional human chorionic gonadotropin, 265 and topical 9-cis-retinoic acid gel (alitretinoin). 266 The use of antiviral agents with activity against HHV-8 has also been considered as a therapeutic alternative.…”

Section: Treatmentmentioning

confidence: 99%

Cutaneous malignancy and human immunodeficiency virus disease

Wilkins

Turner

Dolev

et al. 2006

Journal of the American Academy of Dermatology

Self Cite

135

View full text Add to dashboard Cite

“…Alternative local treatments include intralesional chemotherapy, radiation therapy, laser therapy, and cryotherapy. Vinblastine is the most widely used intralesional agent and has a proven response rate of approximately 70% [68]. Although treated lesions may fade and regress, they unfortunately do not resolve completely.…”

Section: Prognosis and Treatmentmentioning

confidence: 99%

AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy

2005

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing cancer, particularly in the later stages of acquired immune deficiency syndrome (AIDS). LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Describe the pathogenesis and clinical presentation of Kaposi's sarcoma, with a special emphasis on Kaposi's sarcoma herpesvirus/human herpesvirus-8, and outline treatment approaches.2. Discuss the pathogenesis, epidemiology, and treatment of AIDS-related lymphomas.3. Discuss the increasing incidence of non-AIDS-defining malignancies such as Hodgkin's lymphoma and plasma cell disorders in patients with HIV infection.4. Explain how, in the era of highly active antiretroviral therapy, both AIDS-related lymphoma and Hodgkin's lymphoma patients may be treated with therapies previously reserved for their immunocompetent counterparts.Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME by guest on May 11, 2018http://theoncologist.alphamedpress.org/ Downloaded fromThis material is protected by U.S.

show abstract

Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome

Cited by 96 publications

References 5 publications

Therapeutic strategies for epidemic Kaposi's sarcoma

Therapeutic strategies for epidemic Kaposi's sarcoma

Cutaneous malignancy and human immunodeficiency virus disease

AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy

Contact Info

Product

Resources

About